Antepartum Monitoring Devices Market By Product Type (Cardiotocography Monitors, Maternal-Fetal Monitors, Handheld Fetal Dopplers, Wireless and Wearable Monitors, Remote Antepartum Monitoring Systems, Central Monitoring and Analysis Software, Transducers, Sensors and Accessories); By Application (Nonstress Testing, Fetal Heart Rate Monitoring, Uterine Activity Monitoring, Maternal Vital-Sign Monitoring, Multiple-Gestation Monitoring, Remote High-Risk Pregnancy Monitoring); By End User (Hospitals and Maternity Centers, Maternal-Fetal Medicine Clinics, OB-GYN Clinics and Practices, Diagnostic and Antenatal Care Centers, Community Health Facilities, Home Care Settings); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Antepartum Monitoring Devices Market: Repeated High-Risk Surveillance and Distributed Care Shift Value Beyond Conventional CTG Hardware

The Global Antepartum Monitoring Devices Market was valued at USD 3.02 billion in 2025 and is projected to reach USD 4.98 billion by 2032, growing at a CAGR of 7.4%, according to Strategic Market Research.

 

The antepartum monitoring devices market operates through a diagnostic and surveillance pathway rather than a surgical or pharmaceutical pathway. Its commercial base includes professional fetal and maternal-fetal monitors used before labor, cardiotocographs, fetal-heart-rate transducers, contraction sensors, wireless patches, centralized review software and physician-prescribed remote monitoring systems. Demand is generated by completed surveillance sessions, installed monitoring capacity, replacement purchases, accessories, software and service rather than by total pregnancy numbers alone.

 

A single monitor can support hundreds of sessions over its operating life, while one high-risk pregnancy may require several nonstress tests during the final weeks of gestation. Capital-equipment purchases are therefore periodic, but clinical utilization is recurring. National birth totals define the upper boundary of the patient funnel; they do not equal monitored pregnancies, tests performed or devices sold. The supporting market assessment identified the antepartum monitoring session—especially an NST or CTG session—as the most relevant demand unit.

 

Global Stillbirth Burden Strengthens the Surveillance Case but Is Not a Market-Size Proxy

Approximately 1.9 million stillbirths occurred worldwide in 2023 at 28 weeks of pregnancy or later. The global rate was 14.3 stillbirths per 1,000 total births, equivalent to approximately one stillbirth every 17 seconds. Sub-Saharan Africa accounted for 50% of the global total and South Asia for another 31%, meaning that more than eight in ten stillbirths occurred in these two regions. The stillbirth rate reached 22.2 per 1,000 total births in sub-Saharan Africa and 16.3 in South Asia, compared with 2.6 in Western Europe. 

The burden supports public-health investment in antenatal care, referral systems and monitoring capacity, particularly in regions where specialist services are difficult to reach. It should not be converted directly into device demand. Not every stillbirth can be predicted through fetal surveillance, many losses occur before routine monitoring begins, and 46% of global stillbirths in 2023 occurred during labor rather than the antepartum period. The commercial opportunity is therefore linked to the number of clinically eligible pregnancies that reach an equipped care setting, not the total number of adverse outcomes. 

The United States records about 21,000 stillbirths annually, affecting approximately one in 175 births. CDC also reports that progress in reducing the national burden has slowed and that stillbirth rates remain unequal across population groups. These figures strengthen the clinical rationale for identifying high-risk pregnancies, but they do not establish the number of patients who will receive NST, CTG or home monitoring. 

 

The Surveillance Pathway Separates Core Device Revenue from Adjacent Tests

Antepartum surveillance combines several methods, but only part of the pathway contributes directly to the device market. Awareness of fetal movement is a low-cost entry point that may prompt clinical assessment when movement changes. It does not generate professional monitoring-equipment revenue unless the patient is referred for an NST, biophysical profile or another formal evaluation.

The NST and CTG pathway forms the core of the addressable device market. Conventional cardiotocographs use fetal-heart-rate and uterine-activity sensors to generate a tracing that clinicians review for fetal response and possible signs of concern. An NST commonly records fetal heart rate for at least 20 minutes, although the session can continue when an adequate tracing is not obtained. For many high-risk pregnancies, surveillance begins around 32 weeks, but timing and frequency vary according to the underlying condition, gestational age and whether intervention would be considered following an abnormal result. ACOG identifies fetal movement assessment, NST, biophysical profile and umbilical-artery Doppler among the principal approaches used to assess fetal well-being. 

Biophysical profiles and Doppler velocimetry support the same high-risk pregnancy pathway but should not be counted entirely within the core monitoring-device market. A BPP combines electronic fetal-heart-rate assessment with ultrasound evaluation of fetal movement, breathing, muscle tone and amniotic-fluid volume. Doppler velocimetry evaluates blood flow in vessels such as the umbilical artery and is especially relevant to pregnancies involving suspected fetal growth restriction. These tests can increase referrals, extend the surveillance episode or be used alongside an NST, but much of their equipment value belongs to the obstetric ultrasound market.

This distinction prevents total ultrasound examinations or fetal-movement checks from being incorrectly converted into CTG equipment demand. Commercial value increases when an initial concern results in repeated professional monitoring, additional appointments or deployment of a home surveillance platform.

 

High-Risk Pregnancy Volume Converts into Repeat Sessions Rather Than One-Time Testing

The United States registered 3,628,934 births in 2024. Gestational diabetes was recorded in 8.5% of births and prepregnancy diabetes in 1.3%. The country also recorded 109,203 twin births and 2,588 triplet-or-higher-order births. These groups are commercially relevant because diabetes, hypertension, suspected growth restriction, multiple gestation, advanced maternal age and previous adverse outcomes can lead to more intensive fetal surveillance. They cannot be added together because the populations overlap and not every pregnancy within a risk category follows the same monitoring schedule.

Maryland claims provide a more direct measure of realized demand. The state’s Medicaid program recorded 45,817 fetal nonstress-test claims in fiscal 2023, compared with 40,915 in fiscal 2021. The increase was approximately 12% over the two-year period. Maryland commercial claims separately included 6,416 NST services among 2,989 participants, equivalent to an average of 2.15 claims per participant in the reported dataset. The figures are state-specific and do not represent a national growth rate, but they confirm that the market is based on recurring sessions rather than one test for each patient.

Repeated use changes hospital purchasing priorities. Equipment reliability, rapid patient turnover, trace storage, central review and service support can matter more commercially than adding a large number of rarely used functions. Specialist maternal-fetal-medicine centers may also require multiple-fetus capability, whereas smaller practices may favor compact systems dedicated to office-based NSTs.

 

Handheld Dopplers, CTGs and Wearables Serve Different Commercial Requirements

Handheld Dopplers form the portable and lower-cost end of the market. They allow clinicians to detect and assess fetal heart rate during routine antenatal visits, community outreach and initial examinations. Their portability supports use in smaller clinics and low-resource settings, but a brief fetal-heart-rate reading does not replace the multi-parameter tracing used for a formal NST.

Stationary and portable CTG systems remain the most established institutional category. These systems commonly combine an ultrasound fetal-heart-rate transducer with a pressure-based contraction sensor. GE HealthCare’s Corometrics 170 is positioned for antepartum NST use in offices and hospitals, while its broader Corometrics portfolio addresses maternal-fetal monitoring in hospital environments. Philips markets the Avalon FM family across fetal and maternal monitoring settings, and Huntleigh, Edan and Bionet compete with hospital and clinic systems covering singleton, twin and selected multiple-gestation applications. 

Wireless systems reduce dependence on belts, cables and fixed bedside positioning. Philips’ Avalon CL architecture connects cableless transducers and pods to Avalon monitors through hospital wireless infrastructure. Selected Avalon CL transducers are designed to support movement and water-based mobility within clinical environments. Their main commercial value lies in patient mobility and institutional workflow rather than replacing hospital supervision. 

The GE HealthCare Novii+ Wireless Patch System is an FDA-cleared, beltless maternal-fetal monitoring system that measures fetal heart rate, maternal heart rate and uterine activity. Its FDA documentation describes it as an ambulatory system for antepartum and intrapartum monitoring, with the antepartum indication beginning at 34 weeks for singleton pregnancies. The product represents a premium hospital-based wireless category rather than a direct-to-consumer device. 

 

Remote Monitoring Expands the Market Beyond Hospital Equipment Rooms

INVU by Nuvo established a regulated pathway for physician-prescribed home NSTs. The FDA-cleared system records fetal heart rate, maternal heart rate and uterine activity in singleton pregnancies from 32 weeks. A healthcare provider schedules the session and reviews the complete tracing through the professional platform. Nuvo’s commercial model also includes device shipment, technical support, patient onboarding and return logistics, showing that remote monitoring revenue depends on a managed service layer in addition to wearable hardware. 

INVU demonstrates how monitoring can move from a capital-equipment sale toward a per-patient or per-episode model. The provider does not merely purchase a belt. It must align prescribing, logistics, clinical review, software access, technical support and payer documentation. This model can create recurring revenue, but it also requires more working capital and operational support than a conventional monitor sale.

Bloomlife MFM-Pro occupies a narrower regulatory position. The FDA cleared it to record maternal and fetal heart rates in singleton pregnancies from 32 weeks in hospitals, clinics, physicians’ offices and the patient’s home under a physician’s order. The cleared device does not measure uterine activity and is explicitly not cleared to conduct a complete nonstress test. Bloomlife describes the full patch-based home NST application as investigational while pursuing clearance for uterine activity and the complete NST indication. Its commercial potential therefore depends partly on future regulatory expansion rather than its existing heart-rate-monitoring clearance alone.

This distinction is important for market sizing. FDA clearance for heart-rate monitoring should not be counted as equivalent to clearance for a full remote NST. Product pipelines may eventually enlarge the home-monitoring segment, but current indications define the presently addressable use cases.

 

Reimbursement Controls Whether Monitoring Volume Supports Equipment Investment

Service reimbursement differs substantially by payer. Maryland commercial claims reported mean reimbursement of USD 85.40 and median reimbursement of USD 74 for an NST. Michigan Medicaid listed a combined professional and technical reimbursement of USD 31.52 in 2025, equal to 68% of the Medicare comparator used in the state report. These are payments for the clinical service, not prices paid to equipment manufacturers, but they affect the purchasing capacity of obstetric practices and outpatient monitoring units.

Medicaid financed 40.2% of U.S. deliveries in 2024. Providers serving a large public-payer population may favor durable monitors, lower acquisition costs and standardized fleets because premium equipment does not automatically create higher reimbursement. Hospitals with more favorable commercial contracts may have greater flexibility to adopt wireless patches, central surveillance systems and software that improves throughput.

Routine monitoring can also be bundled into global obstetric payments. Kaiser Permanente Washington states that routine NSTs are included within the global obstetric package, while qualifying high-risk NSTs may receive separate reimbursement when plan benefits allow. A test may therefore add clinical workload without producing a separate payment. Suppliers selling to practices must demonstrate capacity, documentation or staffing benefits rather than relying solely on the reimbursement attached to each tracing. 

Remote reimbursement remains fragmented. Home monitoring can reduce travel and release clinic rooms, but providers still need staff to prescribe the service, evaluate the trace and respond when results require follow-up. Commercial adoption will depend on whether insurers recognize the remote session, the device supply and the professional review under a workable payment model.

 

Replacement Purchasing Remains the Most Established Revenue Stream

Conventional monitor replacement remains the market’s most dependable capital pathway. Huntleigh publicly listed its Sonicaid Team3 NST monitor at USD 6,297.72 in the United States. The figure is a list price and may exclude accessories, analysis options, service, institutional discounts and other configuration costs, but it provides a public reference for standalone antepartum equipment pricing.

A UK procurement published in 2026 covered ten Huntleigh Team3 fetal monitors with an estimated value of GBP 141,867. Although the notice relates to a hospital labor and delivery department and does not isolate antepartum use, it demonstrates how replacement budgets generate batch equipment orders. Installed-base age, maintenance availability, software compatibility and fleet standardization can sustain purchasing even where national birth numbers are stable or declining.

Hardware competition becomes more price-sensitive when several vendors meet the basic monitoring requirement. Premium value is shifting toward multiple-fetus capability, wireless acquisition, computerized CTG analysis, central review, integration with hospital information systems and dependable service coverage. Buyers will pay more when those capabilities improve throughput or reduce clinical workload, not simply because a product contains additional functions.

 

Recent FDA Clearances Intensify Institutional Competition

Huntleigh received FDA clearance for the Sonicaid Team3 in February 2025 and subsequently expanded the system’s indication to simultaneous triplet fetal-heart-rate monitoring in September 2025. Triplet monitoring applies to a relatively small patient group, but it strengthens the system’s relevance for tertiary hospitals and specialist centers handling complex multiple pregnancies.

Edan Instruments received FDA clearance in August 2025 for the F15A and F15A Air fetal and maternal monitors. The systems are indicated for antepartum examinations and labor-and-delivery monitoring, adding another recent institutional option to the U.S. market.

The clearance activity shows that conventional hospital monitoring remains commercially active alongside remote platforms. Competition is developing across two directions: established manufacturers are adding analysis, mobility and multiple-fetus functions to institutional systems, while newer companies are attempting to transfer part of the surveillance episode into the home.

 

India Is Developing a Distributed Fetal-Monitoring Vendor Base

India’s market is being shaped by hospital demand and the need to extend monitoring into smaller clinics, community programs and remote locations. CareMother markets FetoMax as a connected CTG and NST system for hospitals and distributed pregnancy monitoring. The platform combines portable monitoring equipment with mobile access, placing the company within India’s growing digital maternal-care segment. 

Janitri offers handheld Dopplers, portable CTG systems, beltless patches, remote NST products and hospital software. The company reports that its products have been used by more than 800 hospitals, that it has trained over 1,500 healthcare providers and that its systems have monitored more than 300,000 mothers and newborns across more than ten countries. These are company-reported figures rather than independently audited market-share data, but they demonstrate that lower-cost connected monitoring is moving beyond pilot-stage deployment. 

InnAccel’s Fetal Lite portfolio combines portable Doppler-based NST/CTG monitoring with an ECG- and EMG-based wireless configuration. Its Fetal Lite SU is indicated by the company for use after 36 weeks, while its conventional wireless NST/CTG configuration is indicated after 24 weeks and can be equipped for twin monitoring. InnAccel also reports a 99% fetal-heart-rate accuracy match against conventional cardiotocography in a published study and lists ongoing 100-patient comparative studies in Bengaluru and Chennai. These data indicate active product validation, although company claims should not be treated as evidence of national adoption. 

Indian suppliers are competing less through large centralized monitoring fleets and more through portability, lower infrastructure requirements, remote data access and use in facilities with limited specialist coverage. The strongest commercial opportunity lies in converting community screening into an organized referral pathway rather than selling consumer reassurance devices without clinical oversight.

 

Maternity-Care Deserts Support Remote and Hub-and-Spoke Deployment

More than 35% of U.S. counties were classified as maternity-care deserts in the March of Dimes 2024 assessment. The 1,104 affected counties accounted for more than 150,000 births and lacked both a birthing facility and an obstetric clinician. Repeated travel for late-pregnancy surveillance is particularly difficult in these areas, creating a practical case for remote NSTs, portable equipment in satellite clinics and central review by maternal-fetal-medicine specialists.

The access gap does not mean every pregnancy in a maternity-care desert is eligible for a monitoring device. Adoption still requires a prescribing clinician, connectivity, patient training, reimbursement and a defined process for responding to an abnormal tracing. Remote technology is commercially strongest when it replaces a reimbursed clinic visit, expands specialist capacity or directs high-risk patients to a higher-acuity facility earlier.

Low- and middle-income markets present an additional challenge. The greatest stillbirth burden is concentrated in sub-Saharan Africa and South Asia, but these regions also face the largest constraints in staffing, procurement budgets, maintenance and referral capacity. Portable systems must fit into a broader care pathway; detecting a concerning trace creates limited value when emergency transport or obstetric intervention is unavailable. 

 

North America Provides the Clearest Commercial Evidence

North America currently provides the strongest combination of public claims data, reimbursement evidence, recent device clearances, established hospital buyers and remote-monitoring activity. U.S. demand spans office-based NST monitors, hospital maternal-fetal platforms, wireless patches, central surveillance software and prescription home systems. The region also illustrates the market’s principal constraint: a clinically appropriate test may have very different economics under commercial insurance, Medicaid or a bundled maternity payment.

Europe remains heavily influenced by public procurement and hospital replacement cycles. Large regional birth totals do not produce one uniform commercial market because purchasing frameworks, clinical protocols and reimbursement differ by country. Institutional standardization and long-term service support are likely to remain more important than birth-volume growth.

Asia-Pacific combines high-volume maternity systems with countries experiencing declining births. In Japan and several European markets, replacement, productivity and premium capability may provide more dependable growth than expansion of the pregnancy cohort. India and other emerging markets offer a different pathway centered on portable, connected and lower-cost monitoring that can extend specialist oversight beyond major urban hospitals.

 

Antepartum Monitoring Devices Market Outlook

The market’s future revenue will depend on the number of high-risk pregnancies entering surveillance, monitoring sessions per pregnancy, replacement requirements, reimbursement and the proportion of testing that moves beyond central hospital units.

Stationary and portable CTG systems will retain the broadest installed base. Handheld Dopplers will remain important in routine and community care but will not replace formal NST equipment. Wireless hospital patches can command premium pricing where mobility and signal continuity improve the clinical workflow. Central monitoring and computerized analysis can increase the value of an existing hardware fleet by allowing one clinical team to review several patients or locations.

Home monitoring represents the most visible emerging channel, but it should not be described as an unrestricted substitute for conventional surveillance. INVU has a defined FDA-cleared home NST indication, while Bloomlife’s existing clearance remains limited to fetal and maternal heart-rate monitoring. Future growth requires broader reimbursement, clinically manageable alert volumes, reliable patient support and financially sustainable vendors.

Suppliers with the strongest position will combine dependable hardware with accessories, service, analysis software, data integration and reimbursement support. The market is shifting from the sale of an isolated fetal monitor toward the delivery of a completed monitoring episode across hospitals, outpatient clinics, satellite facilities and selected patient homes. Commercial success will depend on whether the system expands clinical capacity at a cost that hospitals and payers can justify.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.02 Billion
Revenue Forecast in 2032	USD 4.98 Billion
Overall Growth Rate	CAGR of 7.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Cardiotocography Monitors, Maternal-Fetal Monitors, Handheld Fetal Dopplers, Wireless and Wearable Monitors, Remote Antepartum Monitoring Systems, Central Monitoring and Analysis Software, Transducers, Sensors and Accessories
By Application	Nonstress Testing, Fetal Heart Rate Monitoring, Uterine Activity Monitoring, Maternal Vital-Sign Monitoring, Multiple-Gestation Monitoring, Remote High-Risk Pregnancy Monitoring
By End User	Hospitals and Maternity Centers, Maternal-Fetal Medicine Clinics, OB-GYN Clinics and Practices, Diagnostic and Antenatal Care Centers, Community Health Facilities, Home Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising high-risk pregnancy volumes, wider use of nonstress testing, growing demand for wireless and remote fetal monitoring, expansion of maternal-fetal medicine services, increasing focus on continuous antepartum surveillance in hospitals and home care settings
Customization Option	Available upon request